CNS outcomes in EGFR/ALK wild-type NSCLC patients with brain metastases treated with immune checkpoint inhibitors (ICI).

被引：0
|
作者：
Shultz, David Benjamin
Lau, Sally Cm
Poletes, Christopher
Le, Lisa W.
MacKay, Kate
Shepherd, Frances A.
Bradbury, Penelope Ann
Leighl, Natasha B.
Liu, Geoffrey
Sacher, Adrian G.
机构：
[1] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada
[2] Princess Margaret Canc Ctr, Toronto, ON, Canada
[3] Univ Hlth Network, Toronto, ON, Canada
[4] Princess Margaret Canc Ctr, Canc Clin Res Unit, Toronto, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14505
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Clinical outcomes of EGFR plus NSCLC pts treated with immune checkpoint inhibitors (ICI).
    Piotrowska, Zofia
    Cobb, Rosemary G.
    Banwait, Mandeep
    Marcoux, Nicolas
    Mooradian, Meghan
    Dagogo-Jack, Ibiayi
    Lin, Jessica Jiyeong
    Heist, Rebecca Suk
    Shaw, Alice Tsang
    Gainor, Justin F.
    Sequist, Lecia V.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [2] Durability of CNS disease control in NSCLC patients with brain metastases treated with immune checkpoint inhibitors plus cranial radiotherapy
    Lau, Sally C. M.
    Poletes, Christopher
    Le, Lisa W.
    Mackay, Kate M.
    Fares, Aline Fusco
    Bradbury, Penelope A.
    Shepherd, Frances A.
    Tsao, Ming Sound
    Leighl, Natasha B.
    Liu, Geoffrey
    Shultz, David
    Sacher, Adrian G.
    LUNG CANCER, 2021, 156 : 76 - 81
  • [3] Impact of Brain Metastases in Immune Checkpoint Inhibitors (ICI) Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Patients
    Hendriks, L.
    Henon, C.
    Auclin, E.
    Mezquita, L.
    Ferrara, R.
    Audigier-Valette, C.
    Mazieres, J.
    Lefebyre, C.
    Le Moulec, S.
    Cousin, S.
    Duchemann, B.
    Le Pechoux, C.
    Botticella, A.
    Ammari, S.
    Gazzah, A.
    Caramella, C.
    Adam, J.
    Planchard, D.
    De Ruysscher, D.
    Dingemans, A.
    Besse, B.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S384 - S384
  • [4] EGFR inhibitors for wild-type EGFR NSCLC: to use or not to use?
    Jassem, Jacek
    Dziadziuszko, Rafal
    LANCET ONCOLOGY, 2013, 14 (10): : 916 - 917
  • [5] Effectiveness of ALK inhibitors in treatment of CNS metastases in NSCLC patients
    Gil, Michal
    Knetki-Wroblewska, Magdalena
    Nizinski, Przemyslaw
    Strzemski, Maciej
    Krawczyk, Pawel
    ANNALS OF MEDICINE, 2023, 55 (01) : 1018 - 1028
  • [6] Outcome of Patients with NSCLC and Brain Metastases Treated with Immune Checkpoint Inhibitors in a 'Real-Life' Setting
    Skribek, Marcus
    Rounis, Konstantinos
    Makrakis, Dimitrios
    Agelaki, Sofia
    Mavroudis, Dimitris
    De Petris, Luigi
    Ekman, Simon
    Tsakonas, Georgios
    CANCERS, 2020, 12 (12) : 1 - 13
  • [7] Outcomes of Lynch syndrome (LS) patients treated with immune checkpoint inhibitors (ICI).
    Bari, Shahla
    Kim, Richard D.
    Wang, Xia
    Matejcic, Marco
    Muzaffar, Jameel
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [8] Prognostic factors in non-small cell lung cancer (NSCLC) patients (pts) with brain metastases (BM) treated with immune checkpoint inhibitors (ICI)
    Hendriks, L.
    Henon, C.
    Auclin, E.
    Mezquita, L.
    Ferrara, R.
    Valette, C. Audigier
    Mazieres, J.
    Lefebvre, C.
    Le Moulec, S.
    Duchemann, B.
    Le Pechoux, C.
    Botticella, A.
    Ammari, S.
    Gazzah, A.
    Caramella, C.
    Adam, J.
    Planchard, D.
    De Ruysscher, D.
    Dingemans, A-M. C.
    Besse, B.
    ANNALS OF ONCOLOGY, 2018, 29
  • [9] RETROSPECTIVE STUDY OF ERLOTINIB IN PREVIOUSLY TREATED NSCLC PATIENTS WITH WILD-TYPE EGFR
    Nakahara, Yoshiro
    Hosomi, Yukio
    Yomota, Makiko
    Okuma, Yusuke
    Takagi, Yusuke
    Iguchi, Mari
    Okamura, Tatsuru
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (11) : S490 - S490
  • [10] The Strategies and Mechanisms of Immune Checkpoint Inhibitors for Brain Metastases in NSCLC
    Li, Ji
    Wang, Min
    Xu, Shuhui
    Li, Yuying
    Li, Jiatong
    Yu, Jinming
    Zhu, Hui
    FRONTIERS IN PHARMACOLOGY, 2022, 13
12345